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Abstract: Bacterial superantigens (sAgs) are powerful activators of the immune response that trigger
unspecific T cell responses accompanied by the release of proinflammatory cytokines. Streptococcus equi
(S. equi) and Streptococcus zooepidemicus (S. zooepidemicus) produce sAgs that play an important role
in their ability to cause disease. Strangles, caused by S. equi, is one of the most common infectious
diseases of horses worldwide. Here, we report the identification of a new sAg of S. zooepidemicus, SpeS,
and show that mutation of the putative T cell receptor (TCR)-binding motif (YAY to IAY) abrogated
TCR-binding, whilst maintaining interaction with major histocompatibility complex (MHC) class II
molecules. The fusion of SpeS and SpeSY39I to six S. equi surface proteins using two different peptide
linkers was conducted to determine if MHC class II-binding properties were maintained. Proliferation
assays, qPCR and flow cytometry analysis showed that SpeSY39I and its fusion proteins induced
less mitogenic activity and interferon gamma expression when compared to SpeS, whilst retaining
Antigen-Presenting Cell (APC)-binding properties. Our data suggest that SpeSY39I-surface protein
fusions could be used to direct vaccine antigens towards antigen-presenting cells in vivo with the
potential to enhance antigen presentation and improve immune responses.
Keywords: Streptococcus equi; Streptococcus zooepidemicus; superantigen; vaccine; adjuvant; immune
response; strangles; horse
1. Introduction
Streptococcus equi subspecies equi (S. equi) is a host-restricted pathogen that has evolved from the
zoonotic pathogen Streptococcus equi subspecies zooepidemicus (S. zooepidemicus) [1,2]. S. equi is the
causative agent of strangles, a highly contagious disease characterized by pyrexia and abscessation of
the lymph nodes of the head and neck in horses [3,4]. Interestingly, while these two pathogens share ≈
80 % genomic DNA identity with the human pathogen Streptococcus pyogenes (S. pyogenes), several
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studies indicate that a series of genetic changes and laterally acquired elements may have influenced
the evolution and pathogenic specialization of S. equi [5,6].
Superantigens (sAgs) are bacterial mitogens that interfere with the immune response by forming
a linkage between major histocompatibility complex (MHC) class II molecules on antigen-presenting
cells (APCs) and the variable region of the T cell receptor (TCR) β-chain [7]. This interaction results in a
nonspecific T cell activation and overzealous release of proinflammatory cytokines such as IFN gamma
(IFNγ) and tumor-necrosis factor alpha (TNFα) [8–10]. During a conventional immune response, only
one in 106 T cells is activated, whereas sAgs are capable of stimulating 20% of all the T cells, at a
concentration of only 10−15 moles/L in culture [11]. Streptococcal toxic shock syndrome (STSS), caused
by S. pyogenes, is the most severe presentation of invasive streptococcal infections. STSS has been
associated with the production of sAgs and there is evidence that these toxins also contribute to the
pathogenicity of S. equi and S. zooepidemicus [5,12–16].
Commons et al., 2014 proposed a single nomenclature for streptococcal sAgs [13], which we
have used in this article with previous names listed in brackets. S. equi produces four sAgs: SpeH
(SeeH), SpeI (SeeI), SpeK (SeeL) and SpeL (SeeM). These share more than 96% amino acid identity
with those sAgs produced by S. pyogenes [13,17,18]. S. zooepidemicus does not cause strangles, but is
the most frequently isolated opportunistic pathogen of horses and is also able to produce sAgs such
as SpeN (SzeN), SpeP (SzeP), SpeO (SzeF) and orthologues of SpeK (SzeL) and SpeL (SzeM) [16,17].
The production of these sAgs, with the exceptions of SpeH and SpeO, induce the proliferation of equine
peripheral blood mononuclear cells (PBMCs) [15,16]. However, some strains of S. zooepidemicus lack the
presence of sAg-encoding genes, but possess mitogenic activity in vitro, suggesting that they produce
novel sAg-encoding genes that have not yet been identified [5,16]. In particular, we previously noted
that the culture media of S. zooepidemicus strain 1ID00103 (Sz1ID00103), which was isolated from the
blood of a human with meningitis in 2001, had potent mitogenic activity, whilst only a copy of speO was
identified by qPCR [16]. SpeO has little or no mitogenic activity towards equine PBMCs [16] and so we
hypothesized that Sz1ID00103 produced an additional, as yet unidentified sAg.
Herein, we sequenced the genome of Sz1ID00103, identified the presence of a gene encoding a
new sAg, SpeS, and report its immunological activity. Furthermore, we provide a novel method for
fusing recombinant proteins from S. equi to a TCR-binding defective version of this sAg that may have
the potential to improve the effectiveness of vaccines against strangles, which could also be applied to
other infectious diseases in different animal species, including humans.
2. Results
2.1. Identification of SpeS in Streptococcus equi Subspecies Zooepidemicus Strain 1ID00103
The genome sequence of Sz1ID00103 was interrogated to identify novel superantigen-encoding
sequences. As previously reported by Paillot et al., 2010, Sz1ID00103 encoded a copy of speO (szeF) [16].
However, we also identified a novel sequence encoding the putative superantigen, SpeS, which shared
greatest predicted amino acid identity (66%) with SpeC of S. pyogenes (Figure 1A and Figure S1). SpeS
contained both of the superantigen Prosite domains PS00277 and PS00278 in addition to a HxD zinc
binding domain and the YAY sequence, which has been shown to be required for binding of SpeC to
the TCR β-chain (Figure 1B) [19,20].
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Figure 1. Similarity of the novel superantigen SpeS to known superantigens. (A) The amino acid 
sequences of representatives of the 16 known streptococcal superantigens, SpeS and the 
staphylococcal superantigen SEB were obtained. Nomenclature has been standardized in accordance 
with Commons et al., 2014 [13]. The signal sequences were identified using SignalP [21] and 
removed. The remaining predicted amino acid sequences were utilized to generate a maximum 
likelihood tree in MEGA X [22], which was rooted to SEB. The percentage of trees in which the 
associated taxa clustered together is shown next to the branches. The tree is drawn to scale, with 
branch lengths measured in the number of substitutions per site. The red arrows indicate the location 
of the SpeO and SpeS sequences encoded within the Sz1ID00103 genome. Red boxes indicate 
superantigens encoded by S. equi or S. zooepidemicus. (B) Identification of signature domains found in 
superantigens. The amino acid sequence of SpeS was compared to the closest relatives SpeC, SpeJ 
and SpeR to identify motifs typically found in superantigens. The T cell receptor ß-binding motif 
YAY of SpeC [19,20], the consensus sequence Y-G-G-(LIV)-T-x4-N and 
K-x2-(LIVF)-x4-(LIVF)-D-x3-R-x2-L-x5-(LIV)-Y of the superantigen Prosite domains PS00277 and 
PS00278, respectively, and the zinc binding domain, HxD, were fully conserved in SpeS. Consensus 
matching residues are indicated in red. * represents one of the three or four possible amino acids 
indicated in brackets on the line directly below. 
 
Figure 1. Similarity of the novel superantigen SpeS to known superantigens. (A) The amino acid
sequences of representatives of the 16 know streptococcal superantigens, SpeS and t staphylococcal
superantigen SEB were obtained. Nomenclature has been standardized in accordance with Commons
et al., 2014 [13]. The signal sequences were identified using SignalP [21] and removed. The remaining
predicted amino acid sequences were utilized to generate a maximum likelihood tree in MEGA X [22],
which was rooted to SEB. The percentage of trees in which the associated taxa clustered together is
shown next to the branches. The tree is drawn to scale, with branch lengths measured in the number of
substitutions per site. The red arrows indicate the location of the SpeO and SpeS sequences encoded
within the Sz1ID00103 genome. Red boxes indicate superantigens encoded by S. equi or S. zooepidemicus.
(B) Identification of signature domains found in superantigens. The amino acid sequence of SpeS was
compared to the closest relatives SpeC, SpeJ and eR to identify motifs typically found in superantigens.
The T cell recep r ß-binding motif YAY of SpeC [19,20], the consensus sequence Y-G-G-(LIV)-T-x4-N
and K-x2-(LIVF)-x4-(LIVF)-D-x3-R-x2-L-x5-(LIV)-Y of the supera tigen Prosite domains PS00277 and
PS00278, respectively, and the zinc binding domain, HxD, were fully conserved in SpeS. Consensus
matching residues are indicated in red. * represents one of the three or four possible amino acids
indicated in brackets on the line directly below.
2.2. Disruption of the TCR-Binding Site in SpeS Impairs T Cell Proliferation In Vitro While Retaining Binding
to MHC Class II Molecules
Superantigens are powerful T cell mitogens [23]. In order to determine the mitogenic activity
of SpeS, equine PBMCs were analyzed after being cultured for four days with SpeSWT or SpeSY39I at
different concentrations. SpeSY39I contained a tyrosine to isoleucine mutation at codon 39 that changed
the putative TCR-binding motif YAY to IAY. Clusters of cells were observed after 24 h in PBMCs
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that were cultivated with SpeSWT, while SpeSY39I did not stimulate T cell proliferation (Figure 2A).
Proliferation induced by SpeSWT was dose-dependent, with activity present at very low concentrations
(1.25 × 10−5 µg/mL). SpeSY39I did not stimulate proliferation of PBMCs at any of the concentrations
tested up to 1.25 µg/mL (Figure 2B).Int. J. Mol. Sci. 2020, 21, x 5 of 14 
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Cells were captured with a camera at 10× magnification. Pointed arrows indicate the formation of 
clusters of cells after stimulation with SpeSWT. (B) Dose response; a total of 1 × 106 cells/mL PBMCs 
from two different donors were cultured in triplicate with 1/10 dilutions of SpeSWT or SpeSY39I for four 
days and incubated with 3HT for 16 h prior quantification of proliferating cells. Results are shown as 
stimulation index (SI) and error bars represent the standard error of the mean (SEM). (C,D) Flow 
cytometry analysis of SpeSWT (green) and SpeSY39I (purple) binding to MHC class II molecules. (C) 
Equine T8888s and (D) fibroblasts were incubated for 20 min at 4 °C with SpeSWT-Fluorescein 
isothiocyanate (FITC) or SpeSY39I-FITC in PBS, washed and the level of fluorescence was detected. 
Unstained cells (black) were used as a negative control. 
We next investigated whether the ability of SpeS to bind MHC class II molecules was 
maintained in vitro after disruption of its predicted TCR-binding site. SpeSWT and SpeSY39I were 
labeled with fluorescein isothiocyanate (FITC) and used to measure the level of fluorescence 
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was detected in T8888 cells incubated with either SpeSWT-FITC or SpeSY39I-FITC (Figure 2C). In 
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detected (Figure 2D). Therefore, the capacity to bind to MHC class II molecules was unaffected by 
the Y39I mutation. 
Figure 2. SpeSY39I does not stimulate T cell pr lif r tion but maintains its ability to bind major
histocompatibili y complex (MHC) class II molecules i (A) Images of equin peripheral blood
mononuclear cells (PBMCs) stimulated with 1 µg/mL of SpeSWT or SpeSY39I for 24, 48, 72 and 96 h. Cells
were captured with a camera at 10× magnification. Pointed arrows indicate the formation of clusters of
cells after stimulation with SpeSWT. (B) Dose response; a total of 1 × 106 cells/mL PBMCs from two
different donors were cultured in triplicate with 1/10 dilutions of SpeSWT or SpeSY39I for four days and
incubated with 3HT for 16 h prior quantification of proliferating cells. Results re shown as stimulation
index (SI) and error bars repr sent th standard error of the mea (SEM). (C,D) Flow cyt metry analysis
of SpeSWT (green) and SpeSY39I (purple) binding to MHC class II molecules. (C) Equine T8888s and
(D) fibroblasts were incubated for 20 min at 4 ◦C with SpeSWT-Fluorescein isothiocyanate (FITC) or
SpeSY39I-FITC in PBS, washed and the level of fluorescence was detected. Unstained cells (black) were
used as a negative control.
We next investigated whether the ability of SpeS to bind MHC class II molecules was maintained
in vitro after disruption of its predicted TCR-binding site. SpeSWT and SpeSY39I were labeled with
fluorescein isothiocyanate (FITC) and used to measure the level of fluorescence following binding
to equine T8888 cells (MHC class II+) and fibroblasts (MHC cl s II-). Fluorescence was detected in
T8888 cells incubat d with ither Sp SWT-FITC or SpeSY39I-FITC (Figur 2C). In co tras , binding
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of SpeSWT-FITC or SpeSY39I-FITC to fibroblasts lacking MHC class II was not detected (Figure 2D).
Therefore, the capacity to bind to MHC class II molecules was unaffected by the Y39I mutation.
2.3. S. equi Surface Proteins Fused to SpeSY39I Are Devoid of Mitogenic Activity In Vitro
To identify if the fusion of S. equi surface proteins to SpeSWT or SpeSY39I would affect their mitogenic
activity, equine PBMCs were stimulated and analyzed after four days of culture. Six surface proteins
from S. equi (SEQ_0402, SEQ_1959, SEQ_0933, SEQ_2190, SeM and SEQ_0232) were tested. Similar to
SpeSWT alone, stimulation of PBMCs with the recombinant surface proteins fused to SpeSWT resulted
in the formation of big clusters of cells after 24 h (Figure 3A) and stimulation index (SI) values >2.
In contrast, when PBMCs were cultivated with the recombinant proteins fused to SpeSY39I, the SI was
reduced (Figure 3B). The type of peptide linker used (tetra-alanine or glycine-proline-glycine-proline
(GPGP)) did not affect the ability of the fusion proteins to stimulate PBMCs.
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0.01, **** p ≤ 0.0001. 
Figure 3. S. equi surface proteins fused to SpeSY39I lack mitogenic activity in vitro. (A) Images of equine
PBMCs cultured for 24, 48, 72 and 96 h with 1 µg/mL of SEQ_2190 or SEQ_2190 fused to SpeSWT or
SpeSY39I. Images are representative of all the S. equi surface proteins and fusion proteins used. Photos
of the cells were taken with a camera at 10× m gnification. Poi ted arrows show the clusters of cells
formed after being exposed to the Sp SWT fusion protein. (B) Equin PBMCs (1 × 106 cells/mL) from
two different donors were stimulated in triplicate with 1 µg/mL of the S. equi surface proteins alone or
as fusion proteins for four days. 3HT was added for 16 h before measuring the proliferation of cells.
SpeSWT, SpeSY39I and medium alone were used as controls. Results are presented as SI. Data is from
three independent experiments. Error bars correspond to SEM. * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001.
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2.4. S. equi proteins Fused to SpeS Retain Their Ability To Bind to MHC Class II Molecules
Based on the T cell proliferation results, we reduced our candidates to four using only those fused
by the tetra-alanine (ala) peptide linker and measured whether fusion of these surface proteins to SpeS
could enhance binding to MHC class II+ molecules compared to the sAgs alone. To establish the level
of binding, the fusion protein was labeled with FITC and fluorescence was assessed by flow cytometry
in MHC class II+ and MHC class II- equine cells. While MHC class II+ cells were targeted by the fusion
S. equi proteins-FITC, the level of fluorescence (Figure 4A) was slightly weaker than that observed with
the SpeSWT-FITC or SpeSY39I-FITC alone (Figure 2C). No binding by the fusion proteins was detected
when MHC class II- cells were used (Figure 4B).
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Figure 4. S. equi surface proteins fused to SpeSWT or SpeSY39I retain their ability to bind to MHC class
II molecules in vitro. Flow cytometry analysis of SEQ_0402 (blue), SEQ_1959 (red), SEQ_0933 (yellow)
and SEQ_2190 (aqua green) fusion proteins bi ding to MHC class II molecules. (A) Equine T8888s and
(B) fibrobla ts were incu ated for 20 min at 4 ◦C with the FITC-labell d proteins, washed and the level
of fluorescenc analyzed. Unstained cells (black) wer used as a negative control.
2.5. Expression of IFNγ Decreased In Vitro After Stimulation with S. equi Surface Proteins Fused SpeSY39I
In order to de ermine if the lack of mitogenicity correlated with cytokine levels, we determined the
effect of stimulation with he fusion proteins on the expression of cytokines by PBMCs. The selection of
targets primarily included some of the cytokines that act as mediators of toxic shock syndrome [24–27].
The effect of the proteins fused to SpeSWT in PBMCs was compared to responses following exposure to
the proteins fused to SpeSY39I. After 16 hours, we clearly observed higher levels of IFNγ mRNA in
cells that were stimulated with the surface proteins fused to SpeSWT relative to those fused to SpeSY39I;
however this was not statistically significant (Figure 5A). Levels of IFNγ mRNA reached their peak at
24 h where cells exposed to SpeSWT and the WT fusion proteins showed an increment of more than
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double of the IFNγ expression relative to the Y39I SpeS fusions (Figure 5B). After 48 h, cells stimulated
with the WT SpeS fusions continued to show high levels of IFNγ (Figure 5C) followed by a decrease at
72 h (Figure 5D) when all the groups showed similar levels of IFNγ mRNA expression. A significant
reduction in the mRNA expression of TNFα and IL-6 was observed in PBMCs stimulated with most of
the SpeSWT fusion proteins after 48 or 72 h, respectively (Figures S2 and S3). The expression of IL-10
did not vary significantly between groups at any time point, except at 24 h for the SEQ_0933-SpeS
fusion proteins (Figure S4).
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Figure 5. Levels of IFNγ (a proinflammatory cytokine) mRNA expression are reduced in PBMCs
stimulated with SpeSY39I and S. equi surface proteins fused to SpeSY39I. A concentration of 4 × 106 cells
was cultured in duplicate with 1 µg/mL of PBS (control), SpeSWT, SpeSY39I or the fusion proteins for (A)
16 h, (B) 24 h, (C) 48 h and (D) 72 h. Samples were normalized against the housekeeping genes β-actin
and GAPDH. Differences between the experimental samples and control samples were calculated.
Results are from three different experiments where PBMCs from two different donors were used. Error
bars represent SEM. * p ≤ 0.05, ** p ≤ 0.01.
3. Discussion
sAgs play an important role in the disease of animals and humans by interfering with the
development of protective immune responses through the generation of uncontrollable proinflammatory
mitogenic responses [13]. In the case of S. equi, the sAgs SpeI, SpeH, SpeK and SpeL are associated
with its ability to cause strangles and lymph node abscesses, but its mitogenicity is dependent on the
activity of all except SpeH [15]. Interestingly, the presence of sAgs in S. zooepidemicus isolates has been
associated with non-strangles cases of lymph node abscessation [14] and mitogenic activity has been
attributed to the sAgs SpeK, SpeL, SpeN and SpeP [16,17,28]. Nevertheless, genes encoding these sAgs
were not identified in the genomes of several S. zooepidemicus strains that had mitogenic activity [5,16].
From the 165 S. zooepidemicus isolates sequenced by Paillot et al., 2010 [16], 12 contained speO alone
and were mitogenic. SpeO was reported to lack mitogenic activity [14,16] suggesting the presence of
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new genes. From these isolates we sequenced the strain Sz1ID00103, which significantly stimulated
equine PBMCs in vitro, and identified a new potent mitogenic sAg, which we have named SpeS.
When compared to other sAgs, we found that SpeS shared 66% amino acid identity with SpeC of
S. pyogenes and that the T cell receptor ß-binding motif in SpeS was homologous to that of SpeC (YAY)
(Figure 1). Yamaoka et al., 1998 showed that SpeC mutants where the tyrosine (Y), alanine (A) and
tyrosine (Y) were replaced with isoleucine (I), glutamic acid (E) and isoleucine (I) in positions 15, 16
and 17, respectively, had significantly reduced mitogenic activity [20]. For our study, we generated
a Y39I mutant of SpeS (YAY to IAY) which completely impaired T cell proliferation in PBMCs at all
concentrations. Similar to the results showed by Yamaoka et al., 1998, while mutation of the TCR-binding
site in SpeS reduced T cell proliferation, its ability to bind to MHC class II molecules remained intact.
The application of modified sAgs in therapeutic interventions to stimulate protective antibody
responses has been determined [29–31]. A study by Zeppa et al., 2017 used a nonfunctional version of the
sAg SpeA of S. pyogenes to confer protection to mice after nasopharyngeal infection [29]. Furthermore,
due to their effects on APCs, the potential of using sAgs as vaccine adjuvants by coupling TCR-binding
defective sAgs to other molecules to directly deliver antigens to APCs by targeting elements on the cell
surface opened the possibility of using SpeSY39I as a targeting agent against strangles. For instance,
mice vaccinated with the TCR-binding deficient sAg, SMEZ-2 conjugated to ovalbumin showed a 1000-
to 10,000-fold increase in IgG titers with a significant improvement in antigen presentation and T cell
responses with an enhanced antitumor activity [32,33]. Moreover, the potential of cross-presentation
by SMEZ-2 conjugates was demonstrated by pulsing dendritic cells with SMEZ-2 coupled to the
nucleocapsid of hepatitis B virus, which stimulated T cells more effectively than with the capsid
alone [34].
Currently there is no effective vaccine against strangles that provides long-lasting immunity, but
vaccination studies in horses have indicated the potential of multicomponent subunit vaccines, [35–37].
In our study, the aim of using surface proteins from S. equi fused to SpeSY39I was to deliver a prototype
vaccine to target multiple immunogenic components on the cell surface to generate a better immune
response. In support of this strategy, the analysis of the crystal structure of SpeC performed by
Li et al., 2001 [38] suggested the existence of a similar site in the C-terminal region of SpeS available for
fusing other proteins that could potentially mimic antigen presentation and stimulation of T cells in a
conventional way. The sortase-processed surface proteins selected here were previously identified as
immunogenic targets or important components in strangles diagnosis tests [35–37,39].
Additionally, the use of peptide linkers to fuse proteins has been shown to minimize changes in
the protein structure and, in some cases, provide flexibility to the peptide chain [40]. Therefore, we
selected the tetra-alanine (rigid) and GPGP (flexible) linkers and, while some studies support the use
of rigid linkers [41–43] over the two linkers used here, neither made a difference in our in vitro studies.
Interestingly, the fusion proteins did not alter the activity of SpeS as SpeSWT fusions retained the ability
to stimulate T cells and bind to MHC class II molecules, whereas those fused to SpeSY39I did not have
any mitogenic activity but retained the ability to bind to MHC class II molecules.
Finally, we determined how the fusion proteins affected the cytokine response generated by SpeS.
Paillot et al., 2010 showed that the T cell proliferative response induced by S. equi sAgs indicated that
the early synthesis of IFNγ could play an important role in the pathogenesis of strangles [15] but its
direct effect in such response remained to be determined. Here we report a similar response in which
IFNγ levels peaked after two days, but decreased thereafter. Furthermore, the removal of the ability
to bind to TCRs in SpeS was enough to suppress IFNγ production in the presence of SpeSY39I and
its fusion proteins, suggesting that they could be safe for in vivo studies. However, the consistent
expression of TNFα and IL-6 for up to 24 h after exposure to SpeSY39I suggests that the capacity of
superantigens to elicit these cytokines is independent of their interaction with the TCR. Although, the
superantigen–TCR binding function might be involved in regulatory mechanisms since the presence of
the wild-type SpeS fusion proteins significantly reduced the expression of TNFα and IL-6 at later time
points. A deeper study in how the kinetics of the cytokine response develops in vivo may be useful to
understand better the function of SpeS.
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There are studies that indicate that a difference in the cytokine secretion profiles may be dependent
on the type of sAg [25,26,44] as well as their affinity to the TCR Vβ and MHC class II repertoires and
associated T lymphocyte diversity [45]. This could be a reason why we could not detect high levels of
any of the other cytokines studied here following stimulation of equine PBMCs with SpeS. Additionally,
for S. equi infection it has been demonstrated that sAgs have localized active mitogenic activity that
result mainly in TNFα expression in abscesses material and chondroids [12]. This suggests that systemic
sAgs dissemination may be unnecessary or avoided and that the site of infection and associated immune
cells and tissues could also be influencing the synthesis of different cytokines. The measurement of
cytokine levels at earlier time points may be needed, including the use of different detection methods.
Our results show that fusing surface proteins to SpeS may provide access to a new method of antigen
delivery to APCs, however, the activity of these fusion proteins in vivo still requires further study.
4. Materials and Methods
4.1. Bacterial Strains and DNA Extraction
Strain SzID00103 was recovered from the blood of a human case of meningitis in the UK during
2001 and grown on Todd-Hewitt agar in a humidified atmosphere at 37 ◦C containing 5% CO2.
A single colony was inoculated into Todd-Hewitt broth (THB) and grown overnight in at 37 ◦C in a 5%
CO2-enriched atmosphere. Cells were harvested, and chromosomal DNA was extracted according to
the method of Marmur [46] with the addition of 5000 units of mutanolysin (Sigma-Aldrich, Gillingham,
Dorset, UK) and 20 µg of RNase A (Sigma-Aldrich) during the lysis step. DNA was initially sequenced
using a Genome Sequencer-FLX (454 Life Sciences, Roche Applied Sciences, Branford, CT, USA). This
strain was recently resequenced on an Illumina HiSeq DNA sequencer (Illumina, San Diego, CA,
USA) and is available under the accession number ERS134301. Putative sAg-encoding genes were
identified in the Sz1ID000103 genome by searching for coding sequences with similarity to known
sAg-encoding genes.
4.2. Cloning and Purification of speS and Recombinant Fusion Proteins
speS was amplified from Sz1ID00103 DNA using the primers listed in Table S1 and Phusion DNA
polymerase (New England Biolabs, Ipswich, MA, USA) and cloned into pGEX-3X (GE Healthcare, Little
Chalfont, Buckinghamshire, UK). Replacement of a tyrosine with isoleucine at amino acid position 39
(Y39I) in speS was carried out based on its predicted amino acid sequence identity with the TCR-binding
site of SpeC of S. pyogenes [20]. Primers encoding the desired modification (Table S1) were used to
mutate the plasmid containing the speS wild-type sequence. The resulting products were digested
with DpnI to remove carried over parental plasmid DNA and the mutated speS gene was transformed
into competent cells and sequenced using an ABI3100 DNA sequencer (Applied Biosciences, Waltham,
MA, USA) and data were analyzed with Seqman (DNASTAR, Madison, WI, USA).
DNA encoding S. equi surface proteins was amplified from S. equi strain 4047 (Se4047) genomic
DNA and fused to SpeSWT or SpeSY39I by PCR. To enable movement between SpeS and the S. equi
recombinant proteins, DNA encoding a tetra-alanine or GPGP peptide linker was incorporated between
them. Each of the speS and surface protein-encoding genes were designed to produce gluthatione
S-transferase (GST) fusions where the signal- (for both) and sortase-motif (for the surface proteins)
sequences were omitted. The final PCR products were cut with BamHI and EcoRI (New England
Biolabs), cloned into pGEX-3X (GE Healthcare) and sequenced as described above. The primers used
for cloning and sequencing are listed in Table S1.
Plasmids were transformed into E. coli BL21-DE3 and selected by growth at 37 ◦C in 2× YT
containing 50 µg/mL ampicillin. The production of recombinant proteins was induced by the addition
of 1 mM of IPTG and the cultures incubated at 4 h at 28 ◦C [15]. Cells were harvested and lysed by
digestion with lysozyme for 1 h at 4 ◦C followed by sonication and the GST-proteins were purified
over glutathione Sepharose 4B beads according to the supplier’s protocol (GE Healthcare). Factor Xa
(Amersham Biosciences, Little Chalfont, Buckinghamshire, UK) was then used to cleave the recombinant
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proteins from the GST tag. The concentrations of the purified recombinant proteins were quantified,
and the proteins were stored at −70 ◦C in 50% glycerol. The purity of the proteins was assessed by
polyacrylamide gel electrophoresis and staining with Coomassie blue. All of the recombinant proteins
migrated at the expected sizes and were shown to be greater than 99% pure.
4.3. Stimulation of Peripheal Blood Mononuclear Cells and Thymmidine Incorporation Assay
Equine PBMCs were isolated from heparinized blood by Ficoll density gradient centrifugation and
cultured in RPMI media containing 10% heat inactivated foetal calf serum (FCS), 2 mM l-glutamine,
55 µM 2β-mercaptoethanol and 1% penicillin/streptomycin (all supplied by Sigma, Poole, UK). Medium
alone was used as a negative control. For dose-dependent assays, a total of 106× equine PBMCs were
stimulated with 1/10 dilutions of SpeSWT or SpeSY39I (1.25E-00–1.25E-07 µg/mL) for four days. Pictures
of the culture plates were taken at 24, 48, 72 and 96 h. For proliferation assays using the fusion proteins
a volume of 200 µl of PBMCs at 1 × 106 cells/mL was cultured in triplicate with the recombinant fusion
proteins, SpeSWT or SpeSY39I at the indicated concentrations in flat-bottom 96-well plates.
Proliferation of PBMCs was quantified by [3H]thymidine (3HT) incorporation as previously
described [15]. After 72 h, proliferation of equine PBMCs was measured by overnight incorporation
of 0.5 µCi of 3HT (Amersham Biosciences) into new strands of chromosomal DNA during mitotic
cell division. Radioactivity was measured in a scintillation ß-counter (TopCount NXT, Perkin Elmer,
Chalfont Road, Buckinghamshire, UK). The stimulation index (SI) was calculated as follows: (Response
of stimulated PBMCs) / (Response of unstimulated PBMCs).
4.4. Fluorescein Isothiocyanate (FITC) Labelled Recombinant Fusion Proteins and Detection of MHC
Class II Binding
Recombinant fusion proteins and SpeSWT or SpeSY39I were conjugated to FITC using a FluoReporter
FITC Protein Labelling Kit (Invitrogen, Waltham, MA, USA) according to the manufacturer’s
instructions. Binding to MHC class II molecules was determined by stimulating equine lymphoid
cells (EqT8888 cell line) [47] and equine fibroblasts, at a concentration of 1 × 106 cells/mL, with the
FITC-labelled proteins for 20 min at 4 ◦C. EqT8888 cells, which produce MHC class II molecules,
were cultured in RPMI (44%) and AIM-V (55%) media containing 10% FCS, 2 mM l-glutamine, 0.5%
nonessential amino acids, 0.5% sodium pyruvate, 50 µg/mL gentamycin and 55 µM 2β-mercaptoethanol
(all supplied by Sigma-Aldrich). Primary equine fibroblasts that lack the production of MHC class
II molecules were purified from skin punch biopsies as previously described [48]. Fibroblasts were
cultivated in complete MEM medium (cMEM) containing 10% FCS, 2 mM l-glutamine, 1 mM sodium
pyruvate, 55 µM 2β-mercaptoethanol, 0.25 µg/mL amphotericin B and 1% penicillin/streptomycin
(all supplied by Sigma-Aldrich). Cells were analyzed on an ACEA NovoCyte 2000R flow cytometer
(ACEA Biosciences, San Diego, CA, USA).
4.5. Measurement of IFNγ, TNFα, IL-10 and IL-6 Expression by qPCR
A total of 4 × 106 cells per well were stimulated with the recombinant fusion proteins, SpeSWT or
SpeSY39I (1 µg/mL), or PBS and incubated at 37 ◦C for 16, 24, 48 and 72 h. Cells were resuspended in
lysis buffer and stored at −70 ◦C until needed. RNA extraction was performed with a NucleoSpin
RNA Kit (Macherey-Nagel, Dueren, Germany). RNA samples were diluted to a concentration of 0.5 ng
per well and DNase treated using a High Capacity cDNA Transcription Kit (Thermo Fisher Scientific,
Vilnius, Lithuania) following the manufacturer’s instructions. Forward and reverse primers were
designed to specifically amplify each gene (Table S2). Cytokine expression was determined using
KAPA SYBR Fast Universal Mastermix (Sigma-Aldrich) in a final volume of 10 µL per well as described
previously [14]. A total of 0.5 ng/well of cDNA was amplified under the following conditions: 3 min at
95 ◦C for enzyme activation, 40 cycles of 3 s at 95 ◦C for denaturation, and 40 s at 60 ◦C for anneal
and extension, followed by 0.5 ◦C increments with a SYBR read at each step using a CFX96 Touch
Real Time System (Bio-Rad, Watford, Hertfordshire, UK). Gene expression was determined by the
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comparative threshold cycle method (Ct or ∆∆Ct) where each sample was normalized against the
average of two reference genes, B-actin and GAPDH, and differences between the experimental and
untreated (control) samples were calculated.
4.6. Statistical Analysis
Data was analyzed using GraphPad Prism v. 6.0. The Mann–Whitney U test was used to determine
differences in nonparametric data. All p-values less than 0.05 were considered significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/12/
4467/s1. Table S1. Primers used for cloning and sequencing; Table S2. RT-qPCR reaction primers; Figure S1.
Alignment of the predicted amino acid sequence of SpeS and SpeC; Figure S2. Expression of TNFα by qPCR;
Figure S3. Expression of IL-6 by qPCR; Figure S4. Expression of IL-10 by qPCR.
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